Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer

被引：87

作者：

Hamilton, Chad A. ^{[1
]}

Maxwell, G. Larry ^{[1
]}

Chemofsky, Mildred R. ^{[1
]}

Bernstein, Sarah A. ^{[1
]}

Farley, John H. ^{[1
]}

Rose, G. Scott ^{[1
]}

机构：

[1] Walter Reed Army Med Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Washington, DC 20307 USA

来源：

GYNECOLOGIC ONCOLOGY | 2008年 / 111卷 / 03期

关键词：

Bevacizumab; Intraperitoneal; Ovarian cancer; Ascites; Palliation;

D O I：

10.1016/j.ygyno.2008.04.028

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background. Malignant ascites often has a profound impact on the quality of life of patients with refractory ovarian cancer. Current treatments, including dietary, medical, and procedural are often temporary and unsatisfactory options in patients approaching the end of life. Case. We present a case of an 88 year-old receiving home hospice care with refractory ovarian cancer and severe symptomatic ascites. We performed a paracentesis and treated her with intraperitoneal bevacizumab with dramatic improvement in her ascites and the quality of her final weeks of life. Conclusion. Intraperitoneal bevacizumab may be a useful 1001 in the palliation of malignant ascites and is worthy of further study. Published by Elsevier Inc.

引用

页码：530 / 532

页数：3

共 15 条

[1] Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Burger, Robert A.
Sill, Michael W.
Monk, Bradley J.
Greer, Benjamin E.
Sorosky, Joel I.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5165 - 5171
[2] Experience with bevacizumab in the management of epithelial ovarian cancer
Burger, Robert A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (20) : 2902 - 2908
[3] Byrne AT, 2003, CLIN CANCER RES, V9, P5721
[4] Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Cannistra, Stephen A.
Matulonis, Ursula A.
Penson, Richard T.
Hambleton, Julie
Dupont, Jakob
Mackey, Howard
Douglas, Jeffrey
Burger, Robert A.
Armstrong, Deborah
Wenham, Robert
McGuire, William
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (33) : 5180 - 5186
[5] ELSHAMI K, 2007, J CLIN ONCOL, V25
[6] Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia
Garcia, Agustin A.
Hirte, Hal
Fleming, Gini
Yang, Dongyun
Tsao-Wei, Denice D.
Roman, Lynda
Groshen, Susan
Swenson, Steve
Markland, Frank
Gandara, David
Scudder, Sidney
Morgan, Robert
Chen, Helen
Lenz, Heinz-Josef
Oza, Amit M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) : 76 - 82
[7] Gerber HP, 2005, CANCER RES, V65, P671
[8] What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
Han, Ernest S.
Monk, Bradley J.
[J]. GYNECOLOGIC ONCOLOGY, 2007, 105 (01) : 3 - 6
[9] Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model
Hu, LM
Hofmann, J
Holash, J
Yancopoulos, GD
Sood, AK
Jaffe, RB
[J]. CLINICAL CANCER RESEARCH, 2005, 11 (19) : 6966 - 6971
[10] Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer
Hu, LM
Hofmann, J
Zaloudek, C
Ferrara, N
Hamilton, T
Jaffe, RB
[J]. AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (05) : 1917 - 1924

← 1 2 →